StockpollyBeta
Get App
Popularity #4,070
CLNN · NASDAQ · Biotechnology

Clene (CLNN)

Develops CNM-Au8, an investigational oral therapy for ALS and multiple sclerosis.

$4.53
vs last close−0.01 (−0.22%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000000000000
Cost of revenue000000000000
Gross profit000000000000
10109789466725
Research & development666446144603
333333322222
Selling & marketing000000000000
General & administrative333333322222
Other expenses000000000000
Operating income−10−10−9−7−8−9−4−6−6−7−2−5
70−210−53−2−3−2−6−8
Interest income100000000000
Interest expense111111111111
Other non-operating income−8−11−2−14−412150
Income before tax−2−10−11−7−8−14−1−7−9−9−8−13
Net income from continuing operations−2−10−11−7−8−14−1−7−9−9−8−13
Net income−2−10−11−7−8−14−1−7−9−9−8−13
EPS, basic−$0.38−$1.58−$1.73−$1.06−$1.22−$1.95−$0.09−$0.78−$0.85−$0.93−$0.69−$1.08
EPS, diluted−$0.38−$1.58−$1.73−$1.06−$1.22−$1.95−$0.09−$0.78−$0.85−$0.93−$0.69−$1.08
Weighted average shares, basic66667791010101212
Weighted average shares, diluted66667791010101212
EBITDA−1−9−9−5−7−130−6−8−8−7−5
Depreciation & amortization000000000000
EBIT−1−9−10−6−7−130−7−8−8−7−5